 <h1>Aranesp Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>darbepoetin alfa</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about darbepoetin alfa. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Aranesp.</p><h2>In Summary</h2><p><b>Common side effects of Aranesp include:</b> hypertension and peripheral edema. <b>Other side effects include:</b> congestive heart failure and hypervolemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to darbepoetin alfa: injection solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Injection route (Solution)</p><p>Erythropoiesis-stimulating agents (ESAs) increase the risk for death, myocardial infarction, stroke, and other serious cardiovascular events. Patients with chronic kidney disease (CKD) were at a greater risk for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target Hb levels of greater than 11 g/dL in clinical studies. No trial has identified a Hb target level, ESA dose, or dosing strategy that does not increase these risks. In CKD patients, use the lowest sufficient dose to reduce the need for RBC transfusions. In cancer patients with certain tumor types (ie, breast, non-small cell lung, head and neck, lymphoid, cervical), ESAs shortened overall survival and increased the risk of tumor progression or recurrence in clinical studies. In cancer patients, use the lowest dose needed to avoid RBC transfusions to reduce these risks and the risk of serious cardiovascular and thromboembolic reactions. Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy, and discontinue following the completion of a chemotherapy course. Patients receiving myelosuppressive therapy when the anticipated outcome is cure should not be treated with ESAs.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, darbepoetin alfa (the active ingredient contained in Aranesp) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking darbepoetin alfa:</p><p>
<i>More common</i>
</p><ul>
<li>Accumulation of pus</li>
<li>arm, back, or jaw pain</li>
<li>blurred vision</li>
<li>breathing problems (irregular, noisy, or trouble when resting)</li>
<li>chest pain, discomfort, tightness, or heaviness</li>
<li>chills</li>
<li>confusion</li>
<li>cough producing mucus</li>
<li>decrease in the amount of urine</li>
<li>diarrhea</li>
<li>dilated neck veins</li>
<li>dizziness, fainting, or lightheadedness</li>
<li>dry mouth</li>
<li>fast, slow, or irregular heartbeat</li>
<li>fatigue or tiredness (extreme or unusual)</li>
<li>fever</li>
<li>headache</li>
<li>nausea</li>
<li>pain, tenderness, swelling, or warmth over the injection site</li>
<li>pounding in the ears</li>
<li>rapid breathing</li>
<li>rapid or pounding pulse</li>
<li>skin discoloration at the injection site</li>
<li>stomach pain</li>
<li>sunken eyes</li>
<li>sweating</li>
<li>swelling of the ankles, face, fingers, feet, hands, or lower legs</li>
<li>thirst</li>
<li>trouble with breathing</li>
<li>unconsciousness</li>
<li>vomiting</li>
<li>weight gain</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>difficulty with speaking (slow speech or unable to speak)</li>
<li>double vision</li>
<li>seizures</li>
<li>trouble with thinking</li>
<li>trouble with walking</li>
<li>unable to move the arms, legs, or face muscles (including numbness and tingling)</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Fever</li>
<li>hives, itching, skin rash</li>
<li>pale skin</li>
<li>sore throat</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>cough</li>
<li>joint or muscle pain</li>
<li>red, irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>sores, ulcers, or white spots in mouth or on the lips</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of darbepoetin alfa may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>general feeling of discomfort or illness</li>
<li>lack or loss of strength</li>
<li>loss of appetite</li>
<li>muscle aches, pains, or stiffness</li>
<li>runny nose</li>
<li>shivering</li>
<li>sneezing</li>
<li>trouble with sleeping</li>
</ul><p>
<!-- end injection solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to darbepoetin alfa: injectable solution</i></p><h3>General</h3><p>The most common adverse reactions in patients with chronic kidney disease (CKD) were hypertension, dyspnea, peripheral edema, cough, and procedural hypotension.  The most common adverse reactions in cancer patients receiving chemotherapy were abdominal pain, edema, and thrombovascular events.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 38%), vomiting (up to 27%), diarrhea (up to 20%), constipation (up to 19%), abdominal pain (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Dyspepsia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 32%), fever (up to 19%), peripheral edema (up to 17%), asthenia (up to 16%), edema (up to 12.8%), procedural hypotension (10%), chest pain (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Death, influenza-like symptoms, fluid overload, fall, contusion, pain, arteriovenous graft thrombosis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (up to 31%), hypotension (up to 22%)</p>
<p><b>Common</b> (1% to 10%): Myocardial infarction, thrombotic events, angina pectoris</p>
<p><b>Frequency not reported</b>: Arrhythmia, thromboembolism, thrombosis, thrombophlebitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 20%), back pain (14%), arthralgia (up to 13%), limb pain (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Skeletal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 20%), upper respiratory infection (up to 14%), cough (up to 12%), nasopharyngitis (11%)</p>
<p><b>Common</b> (1% to 10%): Bronchitis, sinusitis, sore throat, pulmonary embolism</p>
<p><b>Frequency not reported</b>: Epistaxis, allergic bronchospasm<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 16%), dizziness (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Cerebrovascular accident/transient ischemic attack, convulsions, paresthesia, hypoesthesia, cerebrovascular disorders, stroke</p>
<p><b>Frequency not reported</b>: Somnolence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Chronic renal failure (15%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (14%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (11%)</p>
<p><b>Common</b> (1% to 10%): Depression, anxiety<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, cellulitis, rash, skin ulcer, alopecia</p>
<p><b>Frequency not reported</b>: Angioedema, urticaria</p>
<p><b>Postmarketing reports</b>: Severe cutaneous reaction<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain, access hemorrhage, access infection, vascular access thrombosis, vascular access complications<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Granulocytopenia</p>
<p><b>Frequency not reported</b>: Anemia, pure red cell aplasia associated with neutralizing antibodies to erythropoietin<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Metastatic neoplasm<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Serious allergic reaction, hypersensitivity reaction, anaphylactic reaction<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Aranesp (darbepoetin alfa)." Amgen, Thousand Oaks, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Aranesp (darbepoetin alfa)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: recombinant human erythropoietins</li>
<li>FDA Alerts (11)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Aranesp &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Anemia Associated with Chronic Renal Failure</li>
<li>Anemia, Chemotherapy Induced</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to darbepoetin alfa: injectable solution</i></p><h3>General</h3><p>The most common adverse reactions in patients with chronic kidney disease (CKD) were hypertension, dyspnea, peripheral edema, cough, and procedural hypotension.  The most common adverse reactions in cancer patients receiving chemotherapy were abdominal pain, edema, and thrombovascular events.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 38%), vomiting (up to 27%), diarrhea (up to 20%), constipation (up to 19%), abdominal pain (up to 16%)</p><p><b>Common</b> (1% to 10%): Dyspepsia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 32%), fever (up to 19%), peripheral edema (up to 17%), asthenia (up to 16%), edema (up to 12.8%), procedural hypotension (10%), chest pain (up to 10%)</p><p><b>Common</b> (1% to 10%): Death, influenza-like symptoms, fluid overload, fall, contusion, pain, arteriovenous graft thrombosis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (up to 31%), hypotension (up to 22%)</p><p><b>Common</b> (1% to 10%): Myocardial infarction, thrombotic events, angina pectoris</p><p><b>Frequency not reported</b>: Arrhythmia, thromboembolism, thrombosis, thrombophlebitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 20%), back pain (14%), arthralgia (up to 13%), limb pain (up to 11%)</p><p><b>Common</b> (1% to 10%): Skeletal pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (up to 20%), upper respiratory infection (up to 14%), cough (up to 12%), nasopharyngitis (11%)</p><p><b>Common</b> (1% to 10%): Bronchitis, sinusitis, sore throat, pulmonary embolism</p><p><b>Frequency not reported</b>: Epistaxis, allergic bronchospasm<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 16%), dizziness (up to 14%)</p><p><b>Common</b> (1% to 10%): Cerebrovascular accident/transient ischemic attack, convulsions, paresthesia, hypoesthesia, cerebrovascular disorders, stroke</p><p><b>Frequency not reported</b>: Somnolence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (15%)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Chronic renal failure (15%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (14%)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (11%)</p><p><b>Common</b> (1% to 10%): Depression, anxiety<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, cellulitis, rash, skin ulcer, alopecia</p><p><b>Frequency not reported</b>: Angioedema, urticaria</p><p><b>Postmarketing reports</b>: Severe cutaneous reaction<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site pain, access hemorrhage, access infection, vascular access thrombosis, vascular access complications<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Granulocytopenia</p><p><b>Frequency not reported</b>: Anemia, pure red cell aplasia associated with neutralizing antibodies to erythropoietin<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Metastatic neoplasm<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Serious allergic reaction, hypersensitivity reaction, anaphylactic reaction<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Aranesp (darbepoetin alfa)." Amgen, Thousand Oaks, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Aranesp (darbepoetin alfa)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>4 Reviews</li>
<li>Drug class: recombinant human erythropoietins</li>
<li>FDA Alerts (11)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Aranesp &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Anemia Associated with Chronic Renal Failure</li>
<li>Anemia, Chemotherapy Induced</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>